drugset / Trial / NCT03711500

D-serine Augmentation of Neuroplasticity

NCT03711500 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the optimal dose of D-serine treatment over three sessions of a program designed to measure auditory plasticity.

Timeline

Start
2019-03-13
Primary completion
2021-04-30
Completion
2021-04-30

Outcome

Met primary endpoint

paper There was a significant overall treatment effect for plasticity improvement (p = .014). PMID 36958998 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject D-serine Unknown 80 mg/kg —
Subject D-serine Unknown 100 mg/kg —
Subject D-serine Unknown 120 mg/kg —